Vivani Medical Inc is a clinical stage biopharmaceutical company which develops miniature, ultra long-acting subdermal drug implant candidates utilizing its proprietary NanoPortal technology, which is designed to enable reversible, ultra long-acting, near constant-rate delivery of a broad range of medicines to treat chronic diseases. Vivani uses this platform technology to develop, and potentially commercialize, drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases, including medication non-adherence, drug tolerability and administration challenges faced by certain patients. It operates in two segments the Biopharm Division and Neurostimulation Division.
Last trade$1.07
Day change+$0.05 (+4.90%)
Day range$0.967 – $1.10
Volume163,572
Market cap$92M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$92.01M
Price / earnings
—
Price / book
6.96×
Price / sales
—
EV / sales
—
EV / EBITDA
-2.86×
Profitability
Earnings per share
-$0.30
Return on assets
-76.56%
Return on equity
-204.52%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
2.4×
Quick ratio
2.4×
Cash ratio
2.22×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$25.72M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for VANI, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$2.51M
$2.42M
$2.43M
$2.18M
$2.21M
$2.7M
$2.34M
$2.16M
Research and development
$5.02M
$4.46M
$4.39M
$4.63M
$4.52M
$4.76M
$4.22M
$4.3M
Total operating expenses
$7.53M
$6.37M
$6.82M
$6.81M
$6.73M
$7.14M
$6.56M
$6.46M
Operating income
-$7.53M
-$6.37M
-$6.82M
-$6.81M
-$6.73M
-$7.14M
-$6.56M
-$6.46M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$7.25M
-$6.37M
-$6.78M
-$6.63M
-$6.53M
-$7.14M
-$6.3M
-$6.05M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$7.25M
-$6.37M
-$6.78M
-$6.63M
-$6.53M
-$7.14M
-$6.3M
-$6.05M
Net income attributable to common shareholders
-$7.25M
-$6.37M
-$6.78M
-$6.63M
-$6.53M
-$7.14M
-$6.3M
-$6.05M
EBITDA
-$7.4M
-$6.24M
-$6.69M
-$6.7M
-$6.62M
-$7.04M
-$6.46M
-$6.37M
Basic earnings per share
-$0.08
-$0.07
-$0.08
-$0.09
-$0.11
-$0.12
-$0.11
-$0.11
Diluted earnings per share
-$0.08
-$0.07
-$0.08
-$0.09
-$0.11
-$0.12
-$0.11
-$0.11
Recent news
Company coverage with links to the original publishers.
Novo Nordisk, which pioneered GLP-1 weight-loss drugs but lost market leadership to Eli Lilly, is attempting a comeback through product innovation. The company has launched a pill version of Wegovy and partnered with Vivani Medical to develop an implant that could deliver the drug once or twice yearly, potentially revolutionizing convenience in the GLP-1 market. While Eli Lilly maintains a stronger market position and higher valuation, Novo Nordisk's continued innovation could help it regain competitive ground.
EmergingGrowth.com announces the 94th Emerging Growth Conference scheduled for July 15-16, 2026, featuring presentations from 20+ small-cap and emerging growth companies across sectors including mining, technology, healthcare, and renewable energy. The virtual conference allows companies to present their strategies, products, and announcements to the investment community.
Vivani Medical announced a definitive merger agreement to merge its wholly owned subsidiary Cortigent, Inc. with ClearOne, Inc. Under the transaction, Cortigent will become a wholly owned subsidiary of ClearOne, which will be renamed Cortigent Holdings, Inc. and trade under ticker symbol 'CRGT'. ClearOne will raise $10-15 million in concurrent financing. Vivani will receive 12.5 million shares and own 59.4-67.5% of the combined company. The transaction is expected to close in Q3 2026.
Vivani Medical announced a registered direct offering of 1.69 million shares and concurrent private placement of 1.35 million shares at $1.48 per share, raising approximately $4.5 million gross proceeds. The funds will support ongoing research and clinical development of the company's drug implant candidates. Chairman Gregg Williams participated in the private placement.
Vivani Medical is raising approximately $15.7 million through a registered direct offering of 6 million shares and a private placement of 3.7 million shares at $1.62 per share. The proceeds will fund research, clinical development, and general corporate purposes.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.